Omipalisib, also known as GSK2126458, is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity. PI3K inhibitor GSK2126458 binds to and inhibits PI3K in the PI3K/mTOR signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability and inducing apoptotic cell death. Bax is a member of the proapoptotic Bcl2 family of proteins. PI3K, often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.
Related Products:
Idelalisib; Almorexant HCL; IC-87114; Pictilisib; Pictilisib mesylate; XL147; PIK-90; Buparlisib; TG100-115; A66; AS-252424; GSK2636771; CH5132799; 3-methyladenine; AS-604850